Clinical Trial Update: Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of Lisaftoclax (APG-2575) as a monotherapy in indolent lymphomas, including Waldenström macroglobulinemia, marg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
• Indolent Non-hodgkin Lymphoma
• Marginal Zone Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Lisaftoclax (APG-2575)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Indolent Lymphoma, WM | Phase 2 | Status: NOT_YET_RECRUITING